FDA Approval of Roche Cancer Drug Confirms Beginning of New Oncology Era

With nothing more than a passing glance, the U.S. Food & Drug Administration's (FDA) approval of Roche Holdings' (OTC: RHHBY) cancer drug entrectinib last month was a run-of-the-mill announcement. In fact, it was almost boilerplate in its tone and feel.